Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Fate Therapeutics (FATE) Stock Price

News coverage about Fate Therapeutics (NASDAQ:FATE) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Fate Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0760544407296 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

A number of research firms have recently commented on FATE. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Thursday. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Friday, September 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $6.79.

Fate Therapeutics (FATE) traded down 5.41% during midday trading on Friday, reaching $3.85. The company had a trading volume of 245,797 shares. Fate Therapeutics has a 52 week low of $1.80 and a 52 week high of $5.68. The firm has a 50-day moving average price of $4.00 and a 200-day moving average price of $3.69. The company’s market capitalization is $159.45 million.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Analysts expect that Fate Therapeutics will post ($0.97) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/10/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-fate-therapeutics-fate-stock-price.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply